Immix Biopharma, Inc.
IMMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $11,293 | $8,735 | $4,196 | $127 |
| G&A Expenses | $11,382 | $7,406 | $4,023 | $1,225 |
| SG&A Expenses | $11,382 | $7,406 | $4,023 | $1,225 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22,675 | $16,141 | $8,219 | $1,352 |
| Operating Income | -$22,675 | -$16,141 | -$8,219 | -$1,352 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,017 | $572 | -$0 | -$23,026 |
| Pre-Tax Income | -$21,657 | -$15,569 | -$8,219 | -$24,378 |
| Tax Expense | $41 | $26 | $10 | $6 |
| Net Income | -$21,613 | -$15,426 | -$8,230 | -$24,384 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -0.89 | -0.59 | -6.64 |
| % Growth | 14.6% | -50.8% | 91.1% | – |
| EPS Diluted | -0.76 | -0.89 | -0.59 | -6.64 |
| Weighted Avg Shares Out | 28,286 | 17,341 | 13,887 | 3,673 |
| Weighted Avg Shares Out Dil | 28,286 | 17,341 | 13,887 | 3,673 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,017 | $572 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $180 |
| Depreciation & Amortization | $115 | $5 | $2 | $2 |
| EBITDA | -$22,559 | -$16,136 | -$8,217 | -$24,196 |
| % Margin | – | – | – | – |